

Pacira Pharmaceuticals, Inc.
 Form 4
 February 10, 2011

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
MIDDLETON FRED A

(Last) (First) (Middle)

**C/O SANDERLING
 VENTURES, 400 SOUTH EL
 CAMINO REAL, SUITE 1200**

(Street)

SAN MATEO, CA 94402

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

Pacira Pharmaceuticals, Inc. [PCRX]

3. Date of Earliest Transaction
 (Month/Day/Year)
02/08/2011

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|---|------------------|
| | | | Code | V | Amount | (A) or (D) | Price | | |
| Common Stock | 02/08/2011 | | C | | 736,583 | A | (5) 736,583 | I | See Footnote (1) |
| Common Stock | 02/08/2011 | | C | | 14,877 | A | (5) 14,877 | I | See Footnote (2) |
| Common Stock | 02/08/2011 | | C | | 24,871 | A | (5) 24,871 | I | See Footnote (3) |
| Common Stock | 02/08/2011 | | C | | 29,634 | A | (5) 29,634 | I | See |

Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

| | | | | | | | | |
|-----------------|------------|---|---------|---|------------|---------|---|-------------------------------|
| Stock | | | | | | | | Footnote <u>(4)</u> |
| Common Stock | 02/08/2011 | C | 681,715 | A | <u>(5)</u> | 681,715 | I | See Footnote <u>(6)</u> |
| Common Stock | 02/08/2011 | C | 344,355 | A | <u>(7)</u> | 344,355 | I | See Footnote <u>(1)</u> |
| Common Stock | 02/08/2011 | C | 12,058 | A | <u>(7)</u> | 12,058 | I | See Footnote <u>(3)</u> |
| Common Stock | 02/08/2011 | C | 14,366 | A | <u>(7)</u> | 14,366 | I | See Footnote <u>(4)</u> |
| Common Stock | 02/08/2011 | C | 341,788 | A | <u>(7)</u> | 341,788 | I | See Footnote <u>(6)</u> |
| Common Stock | 02/08/2011 | C | 129,445 | A | <u>(8)</u> | 129,445 | I | See Footnote <u>(1)</u> |
| Common Stock | 02/08/2011 | C | 4,533 | A | <u>(8)</u> | 4,533 | I | See Footnote <u>(3)</u> |
| Common Stock | 02/08/2011 | C | 5,400 | A | <u>(8)</u> | 5,400 | I | See Footnote <u>(4)</u> |
| Common Stock | 02/08/2011 | C | 128,479 | A | <u>(8)</u> | 128,479 | I | See Footnote <u>(6)</u> |
| Common Stock | 02/08/2011 | P | 46,379 | A | \$ 7 | 46,379 | I | See Footnote <u>(1)</u> |
| Common Stock | 02/08/2011 | P | 27,931 | A | \$ 7 | 27,931 | I | See Footnote <u>(2)</u> |
| Common Stock | 02/08/2011 | P | 4,297 | A | \$ 7 | 4,297 | I | See Footnote <u>(3)</u> |
| Common Stock | 02/08/2011 | P | 5,119 | A | \$ 7 | 5,119 | I | See Footnote <u>(4)</u> |
| Common Stock | 02/08/2011 | P | 184,131 | A | \$ 7 | 184,131 | I | See Footnote <u>(6)</u> |

Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|---------|--|-----------------|---|----------------------------|
| | | | | | V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Series A Convertible Preferred Stock | (5) | 02/08/2011 | | C | | 736,583 | (5) | (5) | Common Stock | 736,583 |
| Series A Convertible Preferred Stock | (5) | 02/08/2011 | | C | | 14,877 | (5) | (5) | Common Stock | 14,877 |
| Series A Convertible Preferred Stock | (5) | 02/08/2011 | | C | | 24,871 | (5) | (5) | Common Stock | 24,871 |
| Series A Convertible Preferred Stock | (5) | 02/08/2011 | | C | | 29,634 | (5) | (5) | Common Stock | 29,634 |
| Series A Convertible Preferred Stock | (5) | 02/08/2011 | | C | | 681,715 | (5) | (5) | Common Stock | 681,715 |
| Convertible Promissory Notes | (7) | 02/08/2011 | | C | | 344,355 | (7) | (7) | Common Stock | 344,355 |
| Convertible Promissory Notes | (7) | 02/08/2011 | | C | | 12,058 | (7) | (7) | Common Stock | 12,058 |
| Convertible Promissory Notes | (7) | 02/08/2011 | | C | | 14,366 | (7) | (7) | Common Stock | 14,366 |

| | | | | | | | | |
|------------------------------|-----|------------|---|---------|-----|-----|--------------|---------|
| Convertible Promissory Notes | (7) | 02/08/2011 | C | 341,788 | (7) | (7) | Common Stock | 341,788 |
| Convertible Promissory Notes | (8) | 02/08/2011 | C | 129,445 | (8) | (8) | Common Stock | 129,445 |
| Convertible Promissory Notes | (8) | 02/08/2011 | C | 4,533 | (8) | (8) | Common Stock | 4,533 |
| Convertible Promissory Notes | (8) | 02/08/2011 | C | 5,400 | (8) | (8) | Common Stock | 5,400 |
| Convertible Promissory Notes | (8) | 02/08/2011 | C | 128,479 | (8) | (8) | Common Stock | 128,479 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| MIDDLETON FRED A C/O SANDERLING VENTURES 400 SOUTH EL CAMINO REAL, SUITE 1200 SAN MATEO, CA 94402 | X | | | |

Signatures

/s/ Fred
Middleton

02/09/2011

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The securities are held by Sanderling Venture Partners VI, L.P. Mr. Middleton is a managing director of Middleton, McNeil, Mills & Associates VI, LLC, which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P., and he may be deemed to have voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P. Mr. Middleton disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.

(2) The securities are held by Sanderling Ventures Management VI. Mr. Middleton is the owner of Sanderling Ventures Management VI and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management VI. Mr. Middleton disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.

(3) The securities are held by Sanderling VI Beteiligungs GmbH & Co. KG. Mr. Middleton is a managing director of Middleton, McNeil, Mills & Associates VI, LLC, which has the ultimate voting and investment power over shares held of record by Sanderling VI Beteiligungs GmbH & Co. KG, and he may be deemed to have voting and investment power over shares held of record by Sanderling VI Beteiligungs GmbH & Co. KG. Mr. Middleton disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.

(4)

Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

The securities are held by Sanderling VI Limited Partnership. Mr. Middleton is a managing director of Middleton, McNeil, Mills & Associates VI, LLC, which has the ultimate voting and investment power over shares held of record by Sanderling VI Limited Partnership, and he may be deemed to have voting and investment power over shares held of record by Sanderling VI Limited Partnership. Mr. Middleton disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.

- (5) The Series A Convertible Preferred Stock had no expiration date and each share of Series A Convertible Preferred Stock was automatically converted into common stock on a 1-for-1 basis upon the consummation of the Issuer's initial public offering.

The securities are held by Sanderling Venture Partners VI Co-Investment Fund. Mr. Middleton is a managing director of Middleton, McNeil, Mills & Associates VI, LLC, which has the ultimate voting and investment power over shares held of record by Sanderling

- (6) Venture Partners VI Co-Investment Fund, and he may be deemed to have voting and investment power over shares held of record by Sanderling Venture Partners VI Co-Investment Fund. Mr. Middleton disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.

- (7) All principal and accrued interest on the Convertible Promissory Notes was automatically converted into shares of Common Stock upon the consummation of the Issuer's initial public offering.

All principal on the Convertible Promissory Notes was automatically converted into shares of Common Stock upon the consummation of

- (8) the Issuer's initial public offering at a conversion price equal to the per share price of the Common Stock sold in the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.